To further evaluate the clinical relevance of MAOA and HIF1A, we assessed whether elevated MAOA levels in prostate cancers treated with neoadjuvant chemotherapy associated with increased HIF1A in vivo. The gene discussed is MAOA; the disease is prostate carcinoma.